Evidence map›Paper›PMID 37736661›Full record

ArticleHemaSphere2023

ABL-class Genomic Breakpoint Q-PCR: A Patient-specific Approach for MRD Monitoring in Acute Lymphoblastic Leukemia.

Inge van Outersterp, Vincent H J van der Velden, Patricia G Hoogeveen, Goda E Vaitkevičienė, Edwin Sonneveld, Gijs van Haaften, Roland P Kuiper, Udo Zur Stadt, Gabriele Escherich, Judith M Boer and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HemaSphere, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. CML-like biology:Haematologica · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Inge van OutersterpPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.ORCID https://orcid.org/0000-0002-7657-7397
Vincent H J van der VeldenDepartment of Immunology, Laboratory Medical Immunology, Erasmus MC, University Medical Center Rotterdam, The Netherlands.
Patricia G HoogeveenDepartment of Immunology, Laboratory Medical Immunology, Erasmus MC, University Medical Center Rotterdam, The Netherlands.
Goda E VaitkevičienėFaculty of Medicine, Vilnius University, Lithuania.
Edwin SonneveldPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.ORCID https://orcid.org/0000-0002-1869-0957
Gijs van HaaftenDepartment of Genetics, University Medical Center Utrecht, The Netherlands.ORCID https://orcid.org/0000-0003-3033-0329
Roland P KuiperPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Udo Zur StadtDepartment of Pediatric Hematology and Oncology, University Medical Center Hamburg Eppendorf, Germany.ORCID https://orcid.org/0000-0002-3133-9977
Gabriele EscherichDepartment of Pediatric Hematology and Oncology, University Medical Center Hamburg Eppendorf, Germany.ORCID https://orcid.org/0000-0003-3901-8745
Judith M BoerPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Monique L den BoerPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37736661
PMCPMC10511034

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.